Diabetic foot infection: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 13: Line 13:
 
*Anaerobes are more likely to be involved in deeper, more chronic ulcers
 
*Anaerobes are more likely to be involved in deeper, more chronic ulcers
   
== Diagnosis ==
+
==Diagnosis==
   
* Osteomyelitis should be considered in all cases of diabetic foot infection
+
*Osteomyelitis should be considered in all cases of diabetic foot infection
** [[Probe-to-bone test]] should be done routinely
+
**[[Probe-to-bone test]] should be done routinely
** Plain film X-ray can be helpful, though not sensitive
+
**Plain film X-ray can be helpful, though not sensitive
** MRI is the preferred diagnostic test, followed by bone and white cell scan
+
**MRI is the preferred diagnostic test, followed by bone and white cell scan
** The gold standard is still bone biopsy for histopathology and culture
+
**The gold standard is still bone biopsy for histopathology and culture
   
 
==Management==
 
==Management==
Line 96: Line 96:
 
|}
 
|}
   
=== Duration ===
+
===Duration===
  +
{| class="wikitable"
  +
!Site of Infection
  +
!Severity
  +
!Duration
  +
|-
  +
| rowspan="3" |soft tissue only
  +
|mild
  +
|1 to 2 weeks; up to 4 weeks if slow-to-resolve
  +
|-
  +
|moderate
  +
|1 to 3 weeks
  +
|-
  +
|severe
  +
|2 to 4 weeks
  +
|-
  +
| rowspan="4" |bone and joint infection
  +
|postamputation, with no residual infection
  +
|2 to 5 days
  +
|-
  +
|postamputation, with residual soft tissue infection
  +
|1 to 3 weeks
  +
|-
  +
|postamputation, with residual bone infection
  +
|4 to 6 weeks
  +
|-
  +
|no surgery
  +
|≥3 months
  +
|}
   
*After amputation or resection
 
**If good source control, only 2 to 5 days is recommended
 
**If there is persistent infection or necrotic bone, 4 or more weeks
 
 
*Osteomyelitis
 
*Osteomyelitis
 
**Traditionally, 6 weeks of parenteral therapy
 
**Traditionally, 6 weeks of parenteral therapy

Revision as of 19:09, 13 January 2021

Background

Microbiology

Diagnosis

  • Osteomyelitis should be considered in all cases of diabetic foot infection
    • Probe-to-bone test should be done routinely
    • Plain film X-ray can be helpful, though not sensitive
    • MRI is the preferred diagnostic test, followed by bone and white cell scan
    • The gold standard is still bone biopsy for histopathology and culture

Management

Severity Common Pathogens Antibiotics Notes
Mild methicillin-susceptible Staphylococcus aureus, Streptococcus species dicloxacillin qid dosing and very narrow-spectrum
clindamycin active against MRSA but higher risk of CDAD
cephalexin qid dosing
levofloxacin not as effective against Staphylococcus aureus
amoxicillin-clavulanic acid broad-spectrum, includes anaerobic coverage
methicillin-resistant Staphylococcus aureus doxycycline uncertain activity against streptococci
TMP-SMX uncertain activity against streptococci
moderate or severe MSSA, Streptococcus species, Enterobacteriaceae, anaerobes levofloxacin suboptimal against MSSA
cefoxitin
ceftriaxone
ampicillin-sulbactam
moxifloxacin
ertapenem
tigecycline
fluoroquinolone with clindamycin
imipenem-cilastatin
MRSA linezolid
daptomycin
vancomycin
Pseudomonas aeruginosa piperacillin-tazobactam

Duration

Site of Infection Severity Duration
soft tissue only mild 1 to 2 weeks; up to 4 weeks if slow-to-resolve
moderate 1 to 3 weeks
severe 2 to 4 weeks
bone and joint infection postamputation, with no residual infection 2 to 5 days
postamputation, with residual soft tissue infection 1 to 3 weeks
postamputation, with residual bone infection 4 to 6 weeks
no surgery ≥3 months
  • Osteomyelitis
    • Traditionally, 6 weeks of parenteral therapy
    • May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence1

Further Reading

References

  1. ^  Karim Gariani, Truong-Thanh Pham, Benjamin Kressmann, François R Jornayvaz, Giacomo Gastaldi, Dimitrios Stafylakis, Jacques Philippe, Benjamin A Lipsky, İlker Uçkay. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1758.